1. Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How
- Author
-
Jan Damoiseaux and Joyce J. B. C. van Beers
- Subjects
0301 basic medicine ,MONOCLONAL-ANTIBODY ,medicine.medical_treatment ,Cell ,lcsh:QR1-502 ,Review ,Biochemistry ,lcsh:Microbiology ,Neutralization ,DOUBLE-BLIND ,0302 clinical medicine ,Sjö ,Immunodeficiency ,gren’ ,biology ,Sjögren’s disease ,medicine.anatomical_structure ,Sjogren's Syndrome ,Antibody ,Programmed cell death ,immune monitoring ,PATHOPHYSIOLOGY ,CONTROLLED-TRIAL ,Models, Biological ,CLASSIFICATION ,s disease ,03 medical and health sciences ,Immune system ,Monitoring, Immunologic ,B-CELL DEPLETION ,medicine ,Animals ,Humans ,biologics ,RITUXIMAB ,Adverse effect ,Molecular Biology ,030203 arthritis & rheumatology ,Biological Products ,business.industry ,PRIMARY IMMUNODEFICIENCIES ,Immunotherapy ,s syndrome ,medicine.disease ,RHEUMATOID-ARTHRITIS ,030104 developmental biology ,Sjögren’s syndrome ,Immunology ,biology.protein ,business ,ABATACEPT TREATMENT - Abstract
Over the years, a wide variety of therapeutic antibodies has been successfully introduced in the auto-immunology clinic, and many more are on the way. Many of these treatments address either a pathogenic circulating molecule or a cell-bound molecule. Whereas addressing the former target results in neutralization of the soluble factor and binding to the latter target either inhibits cellular function or induces selective cell death. If this targeted molecule or cell is part of the immune system, this therapy evokes a state of immunodeficiency with infections as a possible consequence. Therefore, immune monitoring is needed to prevent such adverse side effects of immunotherapy. In this paper, different immunotherapies used in Sjögren’s syndrome, as well as different approaches to monitoring the immune system, are discussed.
- Published
- 2020